LSTANasdaqPharmaceutical PreparationsFiscal year ends December 31
LISATA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.00−0.03 (-2.91%)
Close on Oct 19, 2026
- Market cap
- $9.11M
- P/E (TTM)
- –
- Dividend yield
- –
Lisata Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Lisata Therapeutics | Industry median |
|---|---|---|
| Market Cap | $9.01M | $163.93M |
| Enterprise Value | -$1.69M | $86.66M |
| PS Ratio | 90.11 | 3.58 |
| PB Ratio | 1.09 | 2.02 |
| P/TBV Ratio | 1.15 | 2.30 |
Enterprise value
| Measure | Lisata Therapeutics | Industry median |
|---|---|---|
| EV / Sales | -16.86 | 2.46 |
Income (trailing twelve months)
| Measure | Lisata Therapeutics | Industry median |
|---|---|---|
| Revenue | $100.00K | $57.94M |
| Operating Income | -$16.43M | -$21.44M |
| Pretax Income | -$15.01M | -$14.45M |
| Net Income | -$14.62M | -$22.46M |
| EBITDA | -$16.36M | -$16.91M |
| EPS (Diluted) | -$1.65 | -$0.83 |
Margins
| Measure | Lisata Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -16427.0% | -44.5% |
| Pretax Margin | -15008.0% | -13.0% |
| Profit Margin | -14621.0% | -39.2% |
| EBITDA Margin | -16363.0% | -31.3% |
| FCF Margin | -12323.0% | -8.85% |
Returns
| Measure | Lisata Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -99.9% | -53.1% |
| Return on Assets (ROA) | -80.8% | -41.0% |
| Return on Invested Capital (ROIC) | -1644.8% | -32.0% |
| Return on Capital Employed (ROCE) | -204.3% | -37.8% |
Growth
| Measure | Lisata Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -90.7% | 6.01% |
Balance sheet
| Measure | Lisata Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $10.44M | $62.42M |
| Net Cash (Debt) | $10.44M | $15.68M |
| Net Cash Per Share | $1.16 | $0.66 |
| Equity (Book Value) | $8.24M | $48.79M |
| Book Value Per Share | $0.91 | $1.36 |
| Tangible Book Value | $7.84M | $23.06M |
| Working Capital | $8.03M | $75.77M |
Financial position
| Measure | Lisata Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 3.69 | 3.30 |
| Quick Ratio | 3.50 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Lisata Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$12.32M | -$12.35M |
| Capital Expenditures | $0 | -$1.06M |
| Free Cash Flow | -$12.32M | -$20.28M |
| FCF Per Share | -$1.37 | -$0.42 |
Efficiency
| Measure | Lisata Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.38 |
| Revenue Per Employee | $4.76K | $398.96K |
| Profits Per Employee | -$696.24K | -$703.34K |
| Employee Count | 21 | 74 |
Dividends and yields
| Measure | Lisata Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -162.3% | -22.8% |
| FCF Yield | -136.8% | -9.15% |
| Buyback Yield | -6.51% | -0.77% |
| Shareholder Yield | -6.51% | 0.00% |
Shares
| Measure | Lisata Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 9,010,940 | 58,179,650 |
| Shares Change (YoY) | 5.09% | 11.1% |
| Shares Change (QoQ) | 0.13% | 0.54% |
| Float | 7,968,800 | 49,287,500 |
| Shares Held by Insiders | 11.6% | 11.6% |
| Shares Held by Institutions | 12.1% | 59.4% |
Taxes
| Measure | Lisata Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$387.00K | $91.50K |
Scores
| Measure | Lisata Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -74.88 | -0.28 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Lisata Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.